Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of the study population are German Products with initial market entry after January 1st, 2025 are now benefiting from less strict pricing guidelines if the studies used for AMNOG benefit assessment included ≥ 5 % German patients.
As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option of a confidential reimbursement amount. The aim is to support pharmaceutical companies whose products are subject to a considerable price decrease after undergoing an AMNOG benefit assessment by offering the option to keep the new price confidential.
WS Value & Dossier GmbH
Your specialists for market access and reimbursement.
Rheinstr. 2
65760 Eschborn
Germany
phone: +49 6173 3941016
fax: +49 6173 39411021
© Copyright 2025 | WS Value Dossier GmbH